Loading…

Radiopharmaceutical tracers for cardiac imaging

Cardiovascular disease (CVD) is the leading cause of death and disease burden worldwide. Nuclear myocardial perfusion imaging with either single-photon emission computed tomography or positron emission tomography has been used extensively to perform diagnosis, monitor therapies, and predict cardiova...

Full description

Saved in:
Bibliographic Details
Published in:Journal of nuclear cardiology 2018-08, Vol.25 (4), p.1204-1236
Main Authors: Manabe, Osamu, Kikuchi, Tatsuya, Scholte, Arthur J.H.A., El Mahdiui, Mohammed, Nishii, Ryuichi, Zhang, Ming-Rong, Suzuki, Eriko, Yoshinaga, Keiichiro
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease (CVD) is the leading cause of death and disease burden worldwide. Nuclear myocardial perfusion imaging with either single-photon emission computed tomography or positron emission tomography has been used extensively to perform diagnosis, monitor therapies, and predict cardiovascular events. Several radiopharmaceutical tracers have recently been developed to evaluate CVD by targeting myocardial perfusion, metabolism, innervation, and inflammation. This article reviews old and newer used in nuclear cardiac imaging.
ISSN:1071-3581
1532-6551
DOI:10.1007/s12350-017-1131-5